2021-11-09T18:13:49Z
2021-11-09T18:13:49Z
2021-05-12
2021-11-09T18:13:49Z
The aim of this work was to explore new therapeutic options against Chagas disease by the in vitro analysis of the biocidal activities of several tambjamine and prodiginine derivatives, against the Trypanosoma cruzi CLB strain (DTU TcVI). The compounds were initially screened against epimastigotes. The five more active compounds were assayed in intracellular forms. The tambjamine MM3 and both synthetic and natural prodigiosins displayed the highest trypanocidal profiles, with IC50 values of 4.52, 0.46, and 0.54 µM for epimastigotes and 1.9, 0.57, and 0.1 µM for trypomastigotes/amastigotes, respectively. Moreover, the combination treatment of these molecules with benznidazole showed no synergism. Finally, oxygen consumption inhibition determinations performed using high-resolution respirometry, revealed a potent effect of prodigiosin on parasite respiration (73% of inhibition at ½ IC50), suggesting that its mode of action involves the mitochondria. Moreover, its promising selectivity index (50) pointed out an interesting trypanocidal potential and highlighted the value of prodigiosin as a new candidate to fight Chagas disease.
Artículo
Versión publicada
Inglés
Tripanosoma; Mitocondris; Malaltia de Chagas; Trypanosoma; Mitochondria; Chagas' disease
MDPI
Reproducció del document publicat a: https://doi.org/10.3390/pharmaceutics13050705
Pharmaceutics, 2021, vol. 13, num. 5, p. 705
https://doi.org/10.3390/pharmaceutics13050705
cc-by (c) Herráez, Rocio et al., 2021
https://creativecommons.org/licenses/by/4.0/